CognitiveLow Risk

P21

Also known as: CNTF fragment, Peptide 21

Half-life:: Unknown

Administration Routes

subcutaneous injectionintranasal

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Derived from CNTF; increases BDNF expression and promotes hippocampal neurogenesis; modulates PI3K/Akt pathway

A CNTF-derived peptide that stimulates neurogenesis and BDNF production. Shows promise for cognitive enhancement and neurodegenerative disease prevention.

Primary Research Areas

neurogenesis
BDNF upregulation
memory enhancement
neuroprotection

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

CNTF-derived pentapeptide fragment studied for cognitive enhancement in animal models. No FDA approval, no NDA or IND. Not on any FDA list. Very limited human research. Research compound.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find P21

No active associated providers listed yet.